Dacomitinib Anhydrous vs Durvalumab

## Dacomitinib Anhydrous vs Durvalumab: Overview

This comparison examines the pharmacological differences between **Dacomitinib Anhydrous** and **Durvalumab**.

## Mechanism of Action

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

## Pharmacokinetics

**Half-life**: Dacomitinib Anhydrous — N/A; Durvalumab — 17 days.

## Chemical Properties

**Type**: Dacomitinib Anhydrous — Small molecule; Durvalumab — Antibody.